Significantly more patients in the bevacizumab group achieved a pathological complete response compared with those treated with chemotherapy alone : 87 ( 22 % , 95 % CI 18-27 ) of 388 patients in the Bev + D-FEC group compared with 66 ( 17 % , 13-21 ) of 393 patients in the D-FEC group ( p = 003 ) .